Quest Diagnostics (DGX) Price & Analysis
DGX Stock Chart & Stats
- Day’s Range
- MXN 4,489.00 - MXN 4,489.00
- 52-Week Range
- MXN 3,112.61 - MXN 4,489.00
- Previous Close
- MXN 4,051.77
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 520.47B
- Enterprise Value
- MXN 31.99B
- Total Cash (Recent Filing)
- MXN 797.00M
- Total Debt (Recent Filing)
- MXN 6.29B
- Price to Earnings (P/E)
- 24.7
- Beta
- -0.04
- Next Earnings
- Feb 04, 2027
- EPS Estimate
- 49.8
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.34%
Bulls Say, Bears Say
Bulls Say
Broad Revenue And Volume Growth
Broad volume and revenue growth across diagnostic information services indicates sustained demand rather than reliance on a single customer or test category. Continued physician, hospital, and consumer adoption can support operating leverage and strengthen Quest’s position as healthcare utilization expands.
Strong Cash Generation
Strong operating and free cash flow gives Quest internally generated resources to fund laboratory capacity, technology investments, acquisitions, and shareholder returns. Improving free cash flow also provides resilience against reimbursement pressure while supporting ongoing business modernization.
Productivity And Diagnostic Innovation
Quest is pairing diagnostic innovation with automation and productivity initiatives, creating multiple avenues for durable efficiency and growth. Advanced testing, AI-enabled laboratory processes, and expanding consumer health services can improve the service mix and support margins over time.
Bears Say
Medicare Reimbursement Pressure
PAMA rate reductions create a structural reimbursement headwind for a meaningful portion of Quest’s testing portfolio. Management expects to offset some of the effect, but the scale and breadth of code cuts could pressure revenue, pricing power, and margins beyond the immediate quarter.
Cost Inflation And Transformation Spending
Persistent wage inflation and higher fuel costs raise the operating burden across Quest’s laboratory and service-center network. Project Nova adds near-term expense while modernization proceeds, so productivity gains must offset both inflation and transformation spending to sustain margin expansion.
Cybersecurity And Patient-data Exposure
Unauthorized access to a system containing patient records creates potential regulatory, remediation, legal, and reputational consequences even though operations have not been materially disrupted. The unresolved scope makes the eventual financial and client impact uncertain over the coming months.
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
What is Quest Diagnostics’s market cap?
When is Quest Diagnostics’s upcoming earnings report date?
How were Quest Diagnostics’s earnings last quarter?
Is Quest Diagnostics overvalued?
Does Quest Diagnostics pay dividends?
What is Quest Diagnostics’s EPS estimate?
How many shares outstanding does Quest Diagnostics have?
What happened to Quest Diagnostics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Quest Diagnostics?
What is the TipRanks Smart Score and how is it calculated?
Quest Diagnostics Stock Smart Score
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis
- Employees
- 57,000
- Website
- www.questdiagnostics.com
- Address
- 500 Plaza Drive, Secaucus, NJ, 07094, US
Quest Diagnostics (DGX) Earnings & Revenues
DGX Company Deck
DGX Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall, supported by 10% revenue growth, 15.4% adjusted EPS growth, broad organic volume gains, improving margins, strong channel performance, productivity initiatives, and raised full-year guidance. The main negative factors were the expected PAMA revenue headwind, broad anticipated rate cuts, wage and fuel cost pressure, additional Project Nova spending, and an early-stage cybersecurity investigation. Management stated that it intends to offset a portion of the PAMA impact and maintained confidence in utilization and underlying demand.
View all MX:DGX earnings summariesDGX Net sales Breakdown
- 97.73% Diagnostic Information Services
- 2.27% DS businesses
DGX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 5 |
| Technical Analysis | 2 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |